Discovery and bioassay of disubstituted β-elemene-NO donor conjugates: synergistic enhancement in the treatment of leukemia / 中国天然药物
Chinese Journal of Natural Medicines (English Ed.)
;
(6): 916-926, 2023.
Artículo
en Inglés
| WPRIM
| ID: wpr-1011003
ABSTRACT
Natural products are essential sources of antitumor drugs. One such molecule, β-elemene, is a potent antitumor compound extracted from Curcuma wenyujin. In the present investigation, a series of novel 13,14-disubstituted nitric oxide (NO)-donor β-elemene derivatives were designed, with β-elemene as the foundational compound, and subsequently synthesized to evaluate their therapeutic potential against leukemia. Notably, the derivative labeled as compound 13d demonstrated a potent anti-proliferative activity against the K562 cell line, with a high NO release. In vivo studies indicated that compound 13d could effectively inhibit tumor growth, exhibiting no discernible toxic manifestations. Specifically, a significant tumor growth inhibition rate of 62.9% was observed in the K562 xenograft tumor mouse model. The accumulated data propound the potential therapeutic application of compound 13d in the management of leukemia.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Sesquiterpenos
/
Bioensayo
/
Leucemia
/
Donantes de Óxido Nítrico
/
Línea Celular Tumoral
/
Proliferación Celular
Límite:
Animales
/
Humanos
Idioma:
Inglés
Revista:
Chinese Journal of Natural Medicines (English Ed.)
Año:
2023
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS